A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study

Table 3 Comparison of peak FEV ₁ for abediterol versus placebo and abediterol versus salbutamol

	Least–squares mean difference (standard error)	95% confidence interval
Abediterol 2.5 μg vs. placebo	0.405 (0.027)	0.353, 0.458
Abediterol 1.25 μg vs. placebo	0.371 (0.027)	0.318, 0.424
Abediterol 0.625 μg vs. placebo	0.322 (0.027)	0.269, 0.375
Abediterol 0.313 μg vs. placebo	0.274 (0.027)	0.221, 0.327
Salbutamol 400 μg vs. placebo	0.353 (0.027)	0.299, 0.406
Abediterol 2.5 μg vs. salbutamol 400 μg	0.0529 (0.0270)	-0.0002, 0.1061
Abediterol 1.25 μg vs. salbutamol 400 μg	0.0181 (0.0269)	-0.0350, 0.0711
Abediterol 0.625 μg vs. salbutamol 400 μg	-0.0308 (0.0269)	-0.839, 0.0223
Abediterol 0.313 μg vs. salbutamol 400 μg	-0.0783 (0.0269)	-0.1313, -0.0253

Data included for comparisons of all doses of abediterol with placebo and with salbutamol.

ISSN: 1471-2466